Invention Grant
- Patent Title: Compounds inhibiting leucine-rich repeat kinase enzyme activity
-
Application No.: US14912761Application Date: 2014-08-18
-
Publication No.: US09718818B2Publication Date: 2017-08-01
- Inventor: Duane DeMong , Thomas J. Greshock , Ronald K. Chang , Xing Dai , Hong Liu , John A. McCauley , Wei Li , Kallol Basu , Jack D. Scott , Michael Miller
- Applicant: MERCK SHARP & DOHME CORP. , Duane DeMong , Thomas J. Greshock , Ronald K. Chang , Xing Dai , Hong Liu , John A. McCauley , Wei Li , Kallol Basu , Jack D. Scott , Michael Miller
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Keith D. MacMillan; John C. Todaro
- International Application: PCT/US2014/051401 WO 20140818
- International Announcement: WO2015/026683 WO 20150226
- Main IPC: A61K31/44
- IPC: A61K31/44 ; C07D471/04 ; C07D498/04 ; C07D519/00 ; C07D487/04
Abstract:
The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Public/Granted literature
- US20160200722A1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY Public/Granted day:2016-07-14
Information query
